Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q4 EPS of ($0.82), $0.10 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $13.6 million versus the consensus estimate of $14.28 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.